Remarkable Results from Patients treated with StemSmart
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Neuroscientific Biopharmaceuticals Ltd. has announced remarkable results from its Special Access Program involving patients treated with StemSmart for fistulising Crohn's disease. Four out of five patients achieved a successful clinical response, demonstrating significant improvement with no serious adverse events reported. This announcement also serves to lift a trading halt that was applied for and granted prior to the release.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neuroscientific Biopharmaceuticals Ltd. on 6ix
In the deck
Story so far
Earlier from Neuroscientific Biopharmaceuticals
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- Successful Clinical Results Achieved under Special Access
- Trading Halt
- Fourth Patient Commences StemSmart MSC Treatment
Later from Neuroscientific Biopharmaceuticals
All Neuroscientific Biopharmaceuticals news releasesFollow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals